retatrutide nafld Retatrutide, the triple G, Glucagon-GIP-GLP-1 based triagonist produces substantial resolution of liver fat #NAFLD in PPL with #obesity #ADA2023 @ADA_DiabetesPro @AmDiabetesAssn #NASH trial coming Retatrutide - “Triple G” |
Description
$6,850) [Figure 6.6]
Phase 1 clinical trial preliminary results are promising for fat reduction, including stubborn fat
(Research has identified mast cells as one of the immune cell types involved in the inflammatory cascades that influence arterial plaque development and lipid-related cardiovascular risk, as I note in my MCAS info page.) In neurological disease , research in animal models of stroke and vascular dementia has shown that GLP-1RAs reduce both microglial activation and neuroinflammation, leading to better protection of the brain from injury and cognitive deterioration
Medicare Part D may cover weight loss drugs if they're prescribed to treat another health condition, like diabetes
Molecular Weight
Most insurance plans cover the diabetes versions, but insurers often restrict access to the weight-loss versions
